Allogeneic day 15/16 gestational fetal liver cells have a 10-fold competitive engraftment advantage over adult bone marrow cells when infused into fetal, but not adult, SCID recipients
| Host . | No. engrafted* . | FL dose† . | BM dose† . | 6 wk . | 5 mo . | ||||
|---|---|---|---|---|---|---|---|---|---|
| % FL . | % BM . | % Host . | % FL . | % BM . | % Host . | ||||
| Fetal | 9/9 | 2.0 | 2.0 | 81 ± 2 | 10 ± 2 | 9 ± 1 | 77 ± 3 | 10 ± 2 | 14 ± 1 |
| Fetal | 6/6 | 0.6 | 2.0 | 57 ± 2 | 31 ± 1 | 12 ± 1 | 56 ± 3 | 23 ± 1 | 21 ± 4 |
| Fetal | 13/16 | 0.2 | 2.0 | 42 ± 4 | 46 ± 4 | 12 ± 1 | 39 ± 3 | 40 ± 3 | 21 ± 1 |
| Adult | 3/5 | 20.0 | 20.0 | 27 ± 13 | 40 ± 5 | 33 ± 10 | 36 ± 3 | 39 ± 3 | 25 ± 10 |
| Adult | 5/7 | 6.0 | 20.0 | 12 ± 5 | 44 ± 5 | 44 ± 5 | 7 ± 5 | 41 ± 5 | 52 ± 8 |
| Adult | 2/7 | 2.0 | 20.0 | 1 ± 0 | 68 ± 4 | 31 ± 4 | 3 ± 1 | 79 ± 2 | 18 ± 3 |
| Host . | No. engrafted* . | FL dose† . | BM dose† . | 6 wk . | 5 mo . | ||||
|---|---|---|---|---|---|---|---|---|---|
| % FL . | % BM . | % Host . | % FL . | % BM . | % Host . | ||||
| Fetal | 9/9 | 2.0 | 2.0 | 81 ± 2 | 10 ± 2 | 9 ± 1 | 77 ± 3 | 10 ± 2 | 14 ± 1 |
| Fetal | 6/6 | 0.6 | 2.0 | 57 ± 2 | 31 ± 1 | 12 ± 1 | 56 ± 3 | 23 ± 1 | 21 ± 4 |
| Fetal | 13/16 | 0.2 | 2.0 | 42 ± 4 | 46 ± 4 | 12 ± 1 | 39 ± 3 | 40 ± 3 | 21 ± 1 |
| Adult | 3/5 | 20.0 | 20.0 | 27 ± 13 | 40 ± 5 | 33 ± 10 | 36 ± 3 | 39 ± 3 | 25 ± 10 |
| Adult | 5/7 | 6.0 | 20.0 | 12 ± 5 | 44 ± 5 | 44 ± 5 | 7 ± 5 | 41 ± 5 | 52 ± 8 |
| Adult | 2/7 | 2.0 | 20.0 | 1 ± 0 | 68 ± 4 | 31 ± 4 | 3 ± 1 | 79 ± 2 | 18 ± 3 |
BALB/c severe combined immunodeficient (SCID) fetuses at day 15/16 of gestation or adult BALB/c SCID adults were injected intraperitoneally or intravenously, respectively, with allogeneic T-cell–depleted adult C57BL/6 CD45.2 bone marrow (BM) cells and C57BL/6 CD45.1 fetal liver (FL) cells harvested at day 15/16 of gestation at indicated cell dosages and ratios. Peripheral blood leukocytes were phenotyped at 6 weeks and 5 months after transplantation. The average percentage ± 1 SEM of cells resulting from each of the allogeneic donor stem cell sources and host is shown.
The number of mice with detectable donor chimerism (≥ 2%) per number of mice that underwent transplantation.
Cell dosages are × 106.